TOTAL: $22.95M | ||||
Year to Date: $432.62M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
BioMarin |
Alliant Pharmaceuticals Inc. |
$7.5 |
Milestone payment |
Triggered by FDA approval of Orapred ODT, a tablet formulation of prednisolone for asthma and other conditions; another $8M will be paid within one year (6/1) |
Cyntellect |
Sigma-Aldrich Corp. |
$2.2 |
Milestone payment |
The equity purchase milestone payment stemmed from the companies' Cell Xpress service commercialization agreement (6/7) |
GTC |
LEO Pharma A/S (Denmark) |
$1 |
Milestone payment |
Triggered by a recommendation for approval from European regulators for the antithrombin product Atryn (6/14) |
Ligand |
Wyeth |
ND |
Milestone payment |
Triggered by Wyeth's submission of a new drug application to the FDA for bazedoxifene as a postmenopausal osteoporosis therapy (6/26) |
Nastech |
Procter & Gamble Pharmaceuticals Inc. |
$7 |
Milestone payment |
Nastech attained a development milestone in their deal to develop PTH1-34, a parathyroid hormone nasal spray, for osteoporosis (6/8) |
Rigel Pharmaceuticals Inc. (RIGL) |
Merck & Co. Inc. |
$1 |
Milestone payment |
Triggered by progress in their 2004 collaboration to explore ubiquitin ligases for treating cancer and other diseases (6/13) |
Seattle |
CuraGen Corp. (CRGN) |
ND |
Milestone payment |
Triggered by CuraGen's initiation of a Phase I trial of the antibody-drug conjugate agent CR011-vcMMAE for treating metastatic melanoma (6/22) |
Sunesis |
Merck & Co. Inc. |
$4.25 |
Milestone payment |
Sunesis met certain preclinical milestones in their deal to develop small-molecule inhibitors of beta-amyloid converting enzyme (6/12) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. |